請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92971完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林志民 | zh_TW |
| dc.contributor.advisor | Jim Jr-Min Lin | en |
| dc.contributor.author | 孟慶璿 | zh_TW |
| dc.contributor.author | Ching-Hsuan Meng | en |
| dc.date.accessioned | 2024-07-09T16:11:21Z | - |
| dc.date.available | 2024-07-10 | - |
| dc.date.copyright | 2024-07-09 | - |
| dc.date.issued | 2024 | - |
| dc.date.submitted | 2024-07-02 | - |
| dc.identifier.citation | 1. E. Guerra-Doce, et al., Scientific Reports, 2023, 13, 4782.
2. S. M. Robinson and B. Adinoff, Behavioral Sciences, 2016. 6, 18 3. C. Suwanwela and V. Poshyachinda, Bulletin on Narcotics, 1986, 38, 41-53. 4. A. M. Rosso, Biomedicine International, 2010, 1, 81-87. 5. 佚名, 神農本草經, 東漢, 卷一, 下經. 6. 苗麗, 太原大學學報, 2007, 8, 22-25. 7. National Alliance on Mental Illness, NAMI Comments on the APA’s Draft Revision of the DSM-V Substance Use Disorders, 2013. 8. B. Rush, An inquiry into the effects of ardent spirits upon the human body and mind: With an account of the means of preventing, and of the remedies for curing them, 1823, 1-3. 9. B. S. Katcher, American Journal of Public Health, 1993, 83, 273-281. 10. C. G. Schütz, S. Ramírez-Vizcaya and T. Froese, Front Psychiatry, 2018, 9, 508. 11. D. F. Musto, Pathways of addiction: opportunities in drug abuse research, 1996, 284-294. 12. L.A. King and A.T. Kicman, Drug Testing and Analysis, 2011. 3, 401-403. 13. 柯雨瑞, 百年來台灣毒品刑事政策變遷之研究[博士論文], 2006, 中央警察大學犯罪防治系. 14. A. Lande, International Organization, 1962,16 ,776-797. 15. M. F. Weaver, J. A. Hopper and E. W. Gunderson, Addiction Science & Clinical Practice, 2015, 10, 8. 16. D. Luethi and M.E. Liechti, Arch Toxicol, 2020. 94, 1085-1133 17. T. Páleníček, M. Balíková, M. Rohanová, T. Novák, J. Horáček, M. Fujáková and C. Höschl, Pharmacology Biochemistry and Behavior, 2011, 98, 130-139. 18. N. Christin and J. Thomas, Analysis of the supply of drugs and new psychoactive substances by Europe-based vendors via darknet markets in 2017–18, 2019, EMCDDA. 19. J.B. Zawilska and D. Andrzejczak, Drug and alcohol dependence, 2015. 157, 1-17. 20. A. Shafi, A. J. Berry, H. Sumnall, D. M. Wood and D. K. Tracy, Therapeutic Advances in Psychopharmacology, 2020, 10, 1-21 21. UNODC, UNODC Early Warning Advisory on New Psychoactive Substances, https://www.unodc.org/wdr2013/en/nps.html. 22. M.R. Varì, S. Pichini1, R. Giorgetti, F. P. Busardò, Forensic Science, 2019, 1 ,1-35. 23. G. Mercieca, S. Odoardi, M. Cassar and S. Strano Rossi, Journal of Pharmaceutical and Biomedical Analysis, 2018, 149, 494-501. 24. R. R. Contrucci, T. M. Brunt, F. Inan, E. J. F. Franssen and L. Hondebrink, Therapeutic Drug Monitoring, 2020, 42, 75-82. 25. R. A. Davies, V. T. Nguyen, J. M. Eltit and R. A. Glennon, ACS Chemical Neuroscience, 2023, 14, 2527-2536. 26. European Monitoring Centre for Drugs and Drug Addiction, European Drug Report Trends and Developments, 2022. 27. R. Le Boisselier, J. Alexandre, V. Lelong-Boulouard and D. Debruyne, Nature, 2016, 539, 369-377. 28. R. Le Boisselier, J. Alexandre, V. Lelong-Boulouard and D. Debruyne, Clinical Pharmacology & Therapeutics, 2017, 101, 220-229. 29. R. A. Glennon, Classical hallucinogens: an introductory overview, NIDA research monograph, 1994, 146, 4-32. 30. G. Zhang and R.W. Stackman Jr, Frontiers in pharmacology, 2015, 6, 225. 31. B. V. Dean, S. J. Stellpflug, A. M. Burnett and K. M. Engebretsen, Journal of Medical Toxicology, 2013, 9, 172-178. 32. D. E. Nichols, Journal of Pharmaceutical Sciences, 1981, 70, 839-849. 33. A. Abiero, C. J. Botanas, L. V. Sayson, R. J. Custodio, J. B. de la Peña, M. Kim, H. J. Leea, J. W. Seoc, I. S. Ryuc, C. M0 Changd, J. S. Yangd, Y. S. Leed, C. G. Jange, H. J. Kima, J. H. Cheonga, Behavioural Brain Research, 2019. 359, 828-835. 34. T. Passie, J. H. Halpern, D. O. Stichtenoth, H. M. Emrich and A. Hintzen, CNS Neuroscience & Therapeutics, 2008, 14, 295-314. 35. B. Pat, "dancing plague of 1518" in Encyclopedia Britannic, https://www.historynet.com/the-dancing-plague-of-1518-historys-oddest-epidemic 36. H. Morris and J. Wallach, Drug testing and analysis, 2014, 6, 614-632. 37. B. Sinner and B. Graf, Modern anesthetics, 2008, 313-333. 38. C. S. D. Wink, G. M. J. Meyer, J. Zapp and H. H. Maurer, Analytical and Bioanalytical Chemistry, 2015, 407, 1545-1557. 39. F. Zapata, J. M. Matey, G. Montalvo, C. García-Ruiz, Microchemical Journal, 2021, 163, 105877. 40. C. Campo-Soria, Y. Chang and D.S. Weiss, British Journal of Pharmacology, 2006, 148, 984-990. 41. A. Alkattan, E. Alsalameen and A. Ahmed, Central Nervous System Depressant Drugs: Updated Review. Preprints 2021, 2021010503, https://doi.org/10.20944/preprints202101.0503.v1 2021. 42. P. M. Beardsley and Y. Zhang, New Psychoactive Substances, 2018, Springer Nature Switzerland. 43. P. M. Wax, C. E. Becker and S.C. Curry, Annals of emergency medicine, 2003, 41, 700-705. 44. A. N. Edinoff, A. N. Edinoff, D. M. Garza, S. P. Vining, M. E. Vasterling, E. D. Jackson, K. S. Murnane, A. M. Kaye, R. N. Fair, Y. J. L. Torres, A. E. Badr, E. M. Cornett, A. D. Kaye, Pain and Therapy, 2023. 12, 399-421. 45. N. Forsgard, M. Salehpour and G. Possnert, Journal of Analytical Atomic Spectrometry, 2010, 25, 74-78. 46. J. S. Tsai and G.L. Lin, Drugs of Abuse: Body Fluid Testing, 2005, Humana Press. 47. J. Beran and L. Kevan, The Journal of Physical Chemistry, 1969, 73, 3866-3876. 48. H. Awad, M.M. Khamis and A. El-Aneed, Applied Spectroscopy Reviews, 2015, 50, 158-175. 49. A. T. James and A. J. Martin, Biochemical Journal, 1952. 50, 679-690. 50. H. Barth, LCGC North America, 2018, 36, 830–835. 51. K. D. Bartle and P. Myers, TrAC Trends in Analytical Chemistry, 2002, 21, 547-557. 52. A. M. Haag, Modern proteomics–sample preparation analysis and practical applications, 2016, Springer Cham. 53. S. Banerjee and S. Mazumdar, InternationalJournal of Analytical Chemistry, 2012. 2012,1-40. 54. Thermo Fisher Scientific, Exactive Series Operating Manual, 2017. 55. A. Kaufmann, Selecting the best Q Exactive Orbitrap mass spectrometer scan mode for your application, 2018. 56. E. D. Becker, Analytical Chemistry, 1993, 65, 295-3020. 57. R. G. Brinson, Molecules, 2021, 26, 7091. 58. X. Liu, Organic Chenistry I, 2021, Kwantlen Polytechnic University. 59. H. Günther, NMR Spectroscopy, 2013, Wiely. 60. G. L. Henderson, Forensic Science International, 1993, 63, 19-29. 61. A. Palmer, S. Pichini, R. Pacifici, P. Zuccaro and A. Lopezi, Clinical Pharmacokinetics, 2000, 38, 95-110. 62. A. J. Jenkins, S. Kerrigan, Principles of forensic toxicology, 2020, Springer Nature Switzerland.. 63. M. Parvez, M. Parvez, L. B. Qhanya1, N. T. Mthakathi1, I. K. R. Kgosiemang1, H. D. Bamal1, N. S. Pagadala, T. Xie, H. Yang, H. Chen, C. W. Theron, R. Monyaki1, S. C. Raselemane1, V.Salewe1, B. L. Mongale1, R. G. Matowane1, S. M. H. Abdalla1, W. I. Booi1, M. Wyk1, D. Olivier1, C. E. Boucher, D. R. Nelson, J. A. Tuszynski, J. M. Blackburn, J. H. Yu, S. S. Mashele1, W. Chen and K. Syed, Scientific Reports, 2016, 6, 33099. 64. M. Zhao, J. Ma, M. Li, Y. Zhang, B. Jiang, X. Zhao, C. Huai ,L. Shen, N. Zhang, L. He and S. Qin, International Journal of Molecular Sciences, 2021. 22, 12808. 65. R. Torre, S. Y. Lahoz1, R. P. Lozano1 and M. Farr, Front in Genet, 2012, 3, 235. 66. N. Awasthi, R. Yadav and D. Kumar, Journal of Molecular Structure, 2023, 1271, 134126. 67. D. Dalvie, R. S. Obach, P. Kang, C. Prakash, C. M. Loi, S. Hurst, A. Nedderman, L. Goulet, E. Smith, H. Z. Bu and D. A. Smith, Chemical Research in Toxicology, 2009, 22, 357-368. 68. S. Asha and M. Vidyavathi, Applied Biochemistry and Biotechnology, 2010, 160, 1699-1722. 69. N. Walle, F. Nordmeier, A. A. Doerr, B. Peters, M. W. Laschke, M. D. Menger, P. H. Schmidt, M. R. Meyer, N. Schaefer, Drug Testing and Analysis, 2021, 13 ,74-90. 70. V. Burkina, V. Burkinaa, M. K. Rasmussenb, N. Pilipenkoc, G. Zamaratskaia, Toxicology, 2017, 375, 10-27. 71. P. Brown, W. P. Brown1, R. M. C. Luengo, K. H. Wolfe, K. P. Byrne and C. D Mrphy, Scientific Reports, 2019, 9, 9240. 72. T. Nawaji, T. Nawaji, N. Yamashita, H. Umeda, S. Zhang, N. Mizoguchi, M. Seki, T. Kitazawa and H. Teraoka, Pharmaceuticals, 2020, 13, 456. 73. C. S. Anselmo, V. F. Sardela, B. F. Matias, A. R. Carvalho, V. P. Sousa, H. M. G. Pereiraa and F. R. A. Netoa, Drug Testing and Analysis, 2017, 9, 1685-1694. 74. E. Prado, R. R. Matos, G. M. L. Gomes, C. B. L. Sá,·I. K. C. Nunes, C. S. Anselmo1, A. S. Oliveira,·L. S. A. Cohen, D. S. Siqueira, M. A. M. Oliveira, J. C. L. Ambrosio, G. V. Costa, F. R. A. Neto, M. C. Padilha and H. M. G. Pereira, Forensic Toxicology, 2021 ,39, 73-88. 75. D. R. Nelson, J. V. Goldstone and J. J. Stegeman, Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120474. 76. V. F. Sardela, C. S. Anselmo1, I. K. C. Nunes, G. R. A. Carneiro1, G. R. C. Santos, A. R. Carvalho, B. J. Labanca1, D. S. Oliveira, W. D. Ribeiro1, A. L. D. Araujo, M. C. Padilha, C. K. F. Lima, V. P. Sousa, F. R. A. Neto, H. M. G. Pereira, Drug Testing and Analysis, 2018, 10, 1657-1669. 77. G. G. Gibson and P. Skett, Introduction to drug metabolism, 2013, Springer. 78. U. A. Meyer, Journal of Pharmacokinetics and Biopharmaceutics, 1996, 24, 449-459. 79. J. N. Johnston, I.D. Henter and C.A. Zarate, Pharmacology & Therapeutics, 2023, 246, 108431. 80. E. M. Thurman and I. Ferrer, Analytical and bioanalytical chemistry, 2010, 397, 2807-2816. 81. R. Wodtke, J. Steinberg, M. Kockerling, R. Loser and C. Mamat, Royal Society of Chemistry, 2018, 8, 40921-40933. 82. U. Antia, M.D. Tingle and B.R. Russell, Journal of Pharmacy and Pharmacology, 2009, 61, 877-882. 83. Y. Masubuchi, S. Hosokawa, T. Horie, T. Suzuki, S. Ohmori, M. Kitada and S. Narimatsu, Drug Metabolism and Disposition, 1994, 22, 909-915. 84. H. Youssef and B. Roselyne, Drug Metabolism and Disposition, 2002, 30, 853. 85. O. V. Olesen and K. Linnet, The Journal of Clinical Pharmacology, 2001, 41, 823-832 86. K. Zaitsu, M. Katagi, H. Tsuchihashi and A. Ishii, Forensic Toxicology, 2014, 32, 1-8. 87. B. T. Lopes, M. J. Caldeira, H. Gaspar and M. M. Alexandra, Frontiers in Chemistry, 2021, 8, 609251. 88. G. Shulman and W. Link, Journal of the American Oil Chemists' Society, 1964, 41, 329-331. 89. S. W. Holman, P. Wright and G.J. Langley, Analytical Chemistry, 2010, 82, 2347-2354. 90. J. Szczepanski, M. J. Dibben, W. Pearson, J. R. Eyler and M. Vala, The Journal of Physical Chemistry A, 2001, 105, 9388-9395. 91. F. Khachik, G. R. Beecher, J. T. Vanderslice and G. Furrow, Analytical chemistry, 1988, 60, 807-811. 92. J. Stone, Spectroscopy Europe, 2018, 6, 15-18. 93. J. L. Algar, D. J. Lawes, A. J. Carroll, D. Caldicott and M. D. McLeod, Drug Testing and Analysis, 2024, 1, 1-11. 94. M. Murari, S. Pesavento, F. Greco, A. Vettori, F. Tagliaro, R. Gottardo, Drug Testing and Analysis, 2024, 16, 629-637. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/92971 | - |
| dc.description.abstract | 毒品犯罪是萬國公罪，多數國家都有嚴格的法律防制毒品犯罪。創造全新的新興精神活性物質以規避既有法規限制，已成新的毒品犯罪模式，確認新型精神活性物質結構，找到其生物體代謝物，進一步從代謝物資訊篩檢出濫用族群，再將新興精神活性物質列入法規規範是圍堵此犯罪的方法。本研究之研究對象為3種以氣相層析質譜法分析，質譜與現有已知毒品皆不相符之粉末證物，經以液相層析軌道阱質譜法確認分子式，並以核磁共振光譜法取得氫譜、碳譜、關聯性磁振頻譜等圖譜確認完整分子結構，進而確認3項毒品分別為1-(4-氟苄基)-4-甲基哌嗪、N-丙基-1,2-二苯乙胺、4-氟-α-吡咯烷基苯異己酮，皆為前所未見的新興精神活性物質。後續以斑馬魚代謝模型模擬新興精神物質在人體代謝的路徑，以浸泡斑馬魚於三種新興精神活性物質水溶液的方式，取得這些新興精神活性物質的代謝物，觀察代謝物參考強度比值隨採樣時間變化趨勢，以液相層析軌道阱質譜法的二次質譜解析代謝物可能結構。最後將斑馬與產生的代謝物溶於人體尿液檢品，並以毒品尿液篩檢之標準作業方法分析這些代謝物，模擬3種新興精神活性物質人體尿液檢品於毒品尿液篩檢完整過程，找出3種新興精神活性物質於實務上最適合用於毒品尿液篩檢的指標代謝物。 | zh_TW |
| dc.description.abstract | Drug crime is a global public offense, and most countries have strict laws to prevent drug-related offenses. The creation of new psychoactive substances to circumvent existing regulations has become a new pattern in drug crimes. Confirming the structures of these new psychoactive substances, identifying their biological metabolites, screening for abusers based on metabolites information, and subsequently incorporating these substances into regulatory frameworks are methods employed to counteract this criminal trend. The study involves three powder samples that don’t match well known drugs in their mass spectrum. Through gas chromatography-mass spectrometry, liquid chromatography-Orbitrap mass spectrometry, and nuclear magnetic resonance spectroscopy, the complete molecular structures of 1-[(4-fluorophenyl)methyl]-4-methylpiperazine, N-(1,2-diphenylethyl)propan-1-amine, 1-(4-fluorophenyl)-4-methyl-2-(pyrrolidin-1-yl)pentan-1-onethe were determined, confirming them as new psychoactive substances which have never seen before. Subsequently, a zebrafish metabolism model was used to simulate the human metabolic behavior in response to the three novel psychoactive substances. Using this model, a variety of metabolites were generated, and the possible structures of these metabolites were analyzed. Following the standard operating procedures for drug urine screening, the metabolites were subjected to analysis to identify the most suitable indicative metabolites among the three new psychoactive substances for practical drug urine screening. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2024-07-09T16:11:21Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2024-07-09T16:11:21Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 國立臺灣大學博士學位論文口試委員會審定書 i
謝誌 ii 中文摘要 iii Abstract iv 目次 v 圖次 viii 表次 xii 第一章 介紹 1 1.1 毒品的發展 1 1.2 新興毒品類別概述 3 1.2.1 合成興奮劑類(synthetic stimulants) 3 1.2.2 合成迷幻藥類(synthetic hallucinogens) 5 1.2.3 合成鎮定劑類(synthetic depressants) 7 1.3 毒品鑑定儀器原理及鑑定方法 8 1.3.1 氣相層析串聯質譜法(gas chromatography tandem mass spectrometry, GC-MS) 9 1.3.2 液相層析串聯軌道阱質譜法(liquid chromatography tandem orbitrap mass spectrometry, LC- Orbitrap MS) 10 1.3.3 核磁共振光譜法(nuclear magnetic resonance spectroscopy, NMR) 14 1.4 毒品代謝物 18 第二章 未知化合物結構確認 21 2.1 樣品來源 21 2.2 分析步驟 22 2.3 氣相層析質譜法 24 2.4 液相層析軌道阱質譜法 24 2.5 核磁共振光譜法分析條件 25 2.6 分析結果 27 2.6.1 氣相層析質譜比對結果 27 2.6.2 液相層析軌道阱質譜法分析結果 29 2.6.3 核磁共振光譜法分析結果 31 2.6.3.1 a-9核磁共振光譜 31 2.6.3.2 a-10核磁共振光譜 37 2.6.3.3 a-11核磁共振光譜 44 第三章 新型精神活性物質代謝物研究 49 3.1 斑馬魚代謝模型 49 3.2 尋找a-9、a-10、a-11代謝物 49 3.2.1 實驗方法 49 3.2.1.1 實驗配置 49 3.2.1.2 樣品前處理 49 3.2.1.3 儀器設定 50 3.2.1.4 數據分析 50 3.2.2 a-9代謝物 52 3.2.2.1 預測a-9可能代謝物 52 3.2.2.2 a-9可能代謝物濃度與採樣時間關係 52 3.2.2.3 a-9可能代謝物與正控制組比對 54 3.2.2.4 a-9可能代謝物與負控制組比對 55 3.2.3 a-10代謝物 56 3.2.3.1 預測a-10可能代謝物 56 3.2.3.2 a-10可能代謝物與採樣時間關係 56 3.2.3.3 a-10可能代謝物與正控制組比對 58 3.2.3.4 a-10可能代謝物與負控制組比對 59 3.2.4 a-11代謝物 60 3.2.4.1 預測a-11可能代謝物 60 3.2.4.2 a-11可能代謝物隨採樣時間變化 60 3.2.4.3 a-11可能代謝物與正控制組比對 62 3.2.4.4 a-11可能代謝物與負控制組比對 62 3.3 a-9、a-10、a-11代謝物結構分析 64 3.4 前處理對代謝物RIR影響 73 3.4.1 實驗方法 73 3.4.2 回溶溶劑與代謝物RIR關係 74 3.4.3 毒品尿液檢驗前處理對代謝物RIR影響 75 3.4.4 尿液基質對代謝物RIR影響 77 第四章 結論 79 參考資料 80 附圖 85 附表 91 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | 毒品代謝物 | zh_TW |
| dc.subject | 新興毒品 | zh_TW |
| dc.subject | 斑馬魚 | zh_TW |
| dc.subject | 液相層析軌道阱質譜法 | zh_TW |
| dc.subject | 氣相層析質譜法 | zh_TW |
| dc.subject | 核磁共振光譜法 | zh_TW |
| dc.subject | drugs’ metabolites | en |
| dc.subject | zebrafish | en |
| dc.subject | liquid chromatography tandem orbitrap mass spectrometry | en |
| dc.subject | nuclear resonance spectroscopy | en |
| dc.subject | new psychoactive substances | en |
| dc.subject | gas chromatography mass spectrometry | en |
| dc.title | 新興精神活性物質及其代謝物鑑定 | zh_TW |
| dc.title | Identification of New Psychoactive Substances and Their Metabolites | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 112-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 余慈顏;陳珮珊;凌永健 | zh_TW |
| dc.contributor.oralexamcommittee | Tsyr-Yan Yu;Pai-shan Chen;Yong-Chien Ling | en |
| dc.subject.keyword | 新興毒品,毒品代謝物,核磁共振光譜法,氣相層析質譜法,液相層析軌道阱質譜法,斑馬魚, | zh_TW |
| dc.subject.keyword | new psychoactive substances,drugs’ metabolites,nuclear resonance spectroscopy,gas chromatography mass spectrometry,liquid chromatography tandem orbitrap mass spectrometry,zebrafish, | en |
| dc.relation.page | 103 | - |
| dc.identifier.doi | 10.6342/NTU202401473 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2024-07-02 | - |
| dc.contributor.author-college | 理學院 | - |
| dc.contributor.author-dept | 化學系 | - |
| 顯示於系所單位： | 化學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-112-2.pdf | 7.05 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。